Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

OBJECTIVES: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. DESIGN: This study aimed to evaluate the reduction in duration of hospitalisation with adequate oxygen...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Int J Infect Dis
Main Authors: Generali, Daniele, Bosio, Giancarlo, Malberti, Fabio, Cuzzoli, Antonio, Testa, Sophie, Romanini, Laura, Fioravanti, Antonio, Morandini, Alessandro, Pianta, Luca, Giannotti, Guglielmo, Viola, Erika Maria, Giorgi-Pierfranceschi, Matteo, Foramitti, Marina, Tira, Rosa Angela, Zangrandi, Ilaria, Chiodelli, Giulia, Machiavelli, Andrea, Cappelletti, Maria Rosa, Giossi, Alessia, De Giuli, Valeria, Costanzi, Chiara, Campana, Chiara, Bernocchi, Ottavia, Sirico, Marianna, Zoncada, Alessia, Molteni, Alfredo, Venturini, Sergio, Giudici, Fabiola, Scaltriti, Maurizio, Pan, Angelo
פורמט: Artigo
שפה:Inglês
יצא לאור: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771302/
https://ncbi.nlm.nih.gov/pubmed/33385581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2020.12.073
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים